

Original citation:

Bosch, Sofie, van Gaal, Nora, Zuurbier, Roy P., Covington, James A., Wicaksono, Alfian, Biezeveld, Maarten H., Benninga, Marc A., Mulder, Chris J., de Boer, Nanne K. H. and de Meij, Tim G. J. (2018) Differentiation between pediatric irritable bowel syndrome and inflammatory bowel disease based on fecal scent : proof of principle study. *Inflammatory Bowel Diseases*. doi:10.1093/ibd/izy151

Permanent WRAP URL:

<http://wrap.warwick.ac.uk/102863>

Copyright and reuse:

The Warwick Research Archive Portal (WRAP) makes this work by researchers of the University of Warwick available open access under the following conditions. Copyright © and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable the material made available in WRAP has been checked for eligibility before being made available.

Copies of full items can be used for personal research or study, educational, or not-for profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

Publisher's statement:

This is a pre-copyedited, author-produced PDF of an article accepted for publication in *Inflammatory Bowel Diseases* following peer review. The version of Bosch, Sofie, van Gaal, Nora, Zuurbier, Roy P., Covington, James A., Wicaksono, Alfian, Biezeveld, Maarten H., Benninga, Marc A., Mulder, Chris J., de Boer, Nanne K. H. and de Meij, Tim G. J. (2018) Differentiation between pediatric irritable bowel syndrome and inflammatory bowel disease based on fecal scent : proof of principle study. *Inflammatory Bowel Diseases* is available online at: <https://doi.org/10.1093/ibd/izy151>

A note on versions:

The version presented here may differ from the published version or, version of record, if you wish to cite this item you are advised to consult the publisher's version. Please see the 'permanent WRAP URL' above for details on accessing the published version and note that access may require a subscription.

For more information, please contact the WRAP Team at: wrap@warwick.ac.uk

1 THE FAECAL SCENT OF PAEDIATRIC IRRITABLE BOWEL SYNDROME AND FUNCTIONAL
2 ABDOMINAL PAIN DIFFERS FROM ACTIVE INFLAMMATORY BOWEL DISEASE BUT NOT FROM
3 HEALTHY STATE: PROOF OF PRINCIPLE STUDY

4 Sofie Bosch* ¹, MD, Nora van Gaal* ¹, MD, Roy P. Zuurbier², MD, James A. Covington³, PhD, Alfian N.
5 Wicaksono³, SSI, Maarten H. Biezeveld⁴, MD, Marc A. Benninga⁵, MD, PhD, Chris J. Mulder¹, MD,
6 PhD, Nanne K.H. de Boer**¹, MD, PhD, Tim G.J. de Meij**⁶, MD

7 * Both first authors contributed equally to this work

8 ** Shared last, listed alphabetically

9

10 ¹ Department of Gastroenterology and Hepatology, VU University Medical Centre, De Boelelaan
11 1117, 1081 HV Amsterdam, The Netherlands

12 ² Department of Paediatrics, Spaarne Gasthuis, Spaarnepoort 1, 2134 TM, Hoofddorp

13 ³ School of Engineering, University of Warwick, Coventry, CV4 7AL, UK

14 ⁴ Department of Paediatrics, OLVG, Oosterpark 9, 1091 AC Amsterdam, The Netherlands

15 ⁵ Paediatric Gastroenterology, Emma Children's Hospital / Academic Medical Centre, Amsterdam, The
16 Netherlands

17 ⁶ Department of Paediatric Gastroenterology, VU University Medical Centre, De Boelelaan 1117, 1081
18 HV Amsterdam, The Netherlands

19

20

1 **Conflicts of interest** None

2 **Funding** None

3 **Financial disclosures**

4 N van Gaal has nothing to declare.

5 S Bosch has nothing to declare.

6 R. Zuurbier has nothing to declare.

7 J.A. Covington has nothing to declare.

8 A. Wicaknoso has nothing to declare.

9 M. Biezeveld

10 MA Benninga

11 CJJ Mulder has served as a principal investigator for TEVA Pharma BV. He has received a
12 research grant from TEVA Pharma BV.

13 NKH de Boer has served as a speaker for AbbVie and MSD. He has served as consultant and
14 principal investigator for TEVA Pharma BV and Takeda. He has received a (unrestricted)
15 research grant from Dr. Falk and Takeda.

16 TGJ de Meij

17

1 **Author contributions**

2 TGJ de Meij was the guarantor of this article.

3 N van Gaal and R Zuurbier collected the faecal samples.

4 R Zuurbier prepared the samples and performed VOC analysis.

5 JA Covington and A Wicaksono analysed the data and generated the results.

6 S Bosch drafted the first version of the manuscript.

7 N van Gaal, R Zuurbier, JA Covington, R Savage, M Biezeveld, M Benninga, CJJ Mulder, NKH

8 de Boer, TGJ de Meij reviewed the manuscript for important intellectual content.

9 S Bosch finalised the manuscript.

10 All authors agreed to the final version of the manuscript.

11 **Running title** VOC analysis using FAIMS to differentiate IBS/FAP-NOS and IBD

12 **Word count** 2821

13 **Key words** Volatile organic compounds, Irritable bowel syndrome, functional abdominal

14 pain, inflammatory bowel disease, biomarkers, paediatrics

15

1 **Corresponding author**

2 Sofie Bosch, MD

3 Department of Gastroenterology and Hepatology

4 VU University Medical Centre

5 Room PK 2X 136

6 De Boelelaan 1117

7 1081 HV Amsterdam

8 T: +31 (0)20 444 07 99

9 F: +31 (0)20 444 05 54.

10 E: s.bosch1@vumc.nl

11 **Non-standard abbreviations**

12 VOC = volatile organic compound

13 FAIMS = field asymmetric ion mobility spectrometry

14 eNose = electronic nose

15 GC-MS = gas chromatography–mass spectrometry

16

17

18

19

20

21

22

1 **Abstract (256 words)**

2 **Background** The diagnostic work-up of paediatric functional gastrointestinal
3 disorders, including irritable bowel syndrome (IBS) and functional abdominal pain – not
4 otherwise specified (FAP-NOS), and discrimination from organic conditions, like
5 inflammatory bowel disease (IBD), commonly includes invasive tests carrying a high burden
6 on patients. Therefore, there is an ongoing need to develop non-invasive diagnostic
7 biomarkers for IBS and FAP-NOS. The aim of this study was to evaluate whether paediatric
8 IBS/FAP-NOS could be discriminated from IBD and healthy controls by faecal VOCs (volatile
9 organic compound) analysis.

10 **Methods** In this multicentre case-control study, IBS/FAP-NOS patients according to the
11 ROME IV criteria, with age and sex matching *de novo* IBD patients aged 4 to 17 years, were
12 recruited from outpatient clinics of three hospitals in Amsterdam, The Netherlands. Healthy
13 controls (HC) were children without gastrointestinal symptoms. Faecal VOCs were analysed
14 by means of field asymmetric ion mobility spectrometry (FAIMS, Lonestar®, Owlstone, UK).

15 **Results** Faecal VOCs of 15 IBS/FAP-NOS, 30 IBD (15UC, 15CD) patients and 15 HC were
16 analysed and compared. Differentiation between IBS/FAP-NOS and IBD was feasible with
17 high accuracy (AUC ± 95%CI, sensitivity, specificity; PPV; NPV; P-values; 0.94 (0.88-1), 1, 0.87,
18 0.79, 1, 0.00000002613). IBS/FAP patients could not be discriminated HC (AUC ± 95%CI,
19 sensitivity, specificity, PPV, NPV, P-values; (0.59 (0.41-0.77), 0.6, 0.3, 0.45, 0.76, 0.1667).

20 **Conclusion** Paediatric IBS/FAP-NOS could be differentiated from IBD by faecal VOC analysis
21 with high accuracy, but not from controls. The latter finding limits the potential of faecal
22 VOCs to serve as diagnostic biomarker for IBS/FAP-NOS. However, it could possibly serve as
23 additional non-invasive biomarker to discriminate between IBS/FAP-NOS and IBD.

24

1 Introduction

2 Irritable bowel syndrome (IBS) and functional abdominal pain – not otherwise specified
3 (FAP-NOS) are gastrointestinal disorders in children. It has a worldwide prevalence of about
4 13% and often lasts for more than five years after the diagnosis has been established (1).

5 Since biochemical diagnostic biomarkers are yet not available, diagnosis relies on the
6 symptom-based ROME IV criteria (2). The ROME IV criteria include that the symptoms
7 cannot be explained by another medical condition after appropriate evaluation.

8 Differentiation between IBS and somatic disorders like inflammatory bowel disease (IBD) can
9 be difficult. To exclude somatic diseases, the diagnostic work-up may include colonoscopy,
10 which carries a high burden on patients, leads to high costs and risk of complications (3, 4).

11 Currently, faecal calprotectin (FCP) is the most commonly used non-invasive diagnostic
12 biomarker to discriminate between IBS/FAP-NOS and IBD, which is characterized by a high
13 sensitivity for mucosal inflammation (0.98, 95%CI 0.95-0.99), but limited specificity (0.68,
14 95% CI 0.50-0.86) (5). Therefore, the search for an accurate, non-invasive biomarker to
15 differentiate between IBD and functional disorders like IBS/FAP-NOS remains.

16

17 Alterations of the intestinal microbiota have been described in IBS/FAP-NOS patients (6).

18 Yet, microbiota analysis is not desirable as a non-invasive biomarker test in clinical practice,
19 as the analysis is complex, time-consuming and expensive (7). Assessment of volatile organic

20 compound (VOC) composition, which are considered to reflect microbiota composition and

21 function, is an upcoming field in metabolomics (8). VOC analysis (i.e. detecting the odours

22 than emanate from a biological sample) has shown potential to serve as a diagnostic

23 biomarker for a broad range of gastrointestinal diseases, in particular those linked to

24 microbial dysbiosis, e.g. *Clostridium difficile* infection, IBD, colorectal cancer and necrotizing

1 enterocolitis (8-11). There are several techniques to analyse VOCs from simple gas sensor
2 arrays to high-end analytical instruments such as gas chromatography/mass spectrometry. A
3 more modern technique finding favour in many fields is Field asymmetric ion mobility
4 spectrometry (FAIMS), which measures the mobility of ions in high electric fields. It is
5 characterized by high reproducibility, relatively low costs and minimal sensor drift (12).

6 Differentiation between IBS, active IBD and healthy controls has been subject of a study on
7 adults, showing high sensitivity (CD 94%, UC 96%, HC 90%) and specificity (CD 82%, UC 80%,
8 HC 80%) (13).

9

10 We hypothesized that paediatric IBD and IBS/FAP-NOS could be distinguished based on
11 differences in faecal VOC composition. The aim of this study was to investigate whether
12 faecal VOC patterns, analysed by FAIMS, could serve as biomarker to distinguish IBS/FAP
13 from IBD and from healthy controls, in a paediatric population.

14

1 **Methods**

2 *Study design*

3 This case-control study was performed at the outpatient clinics of the paediatric
4 (gastroenterology) departments of the tertiary centres VU university medical centre, Emma
5 Children's Hospital, and OLVG Oost (all centres located in Amsterdam, the Netherlands). The
6 study was performed between December 2013 and December 2016.

7

8 *Study participants*

9 Three subgroups were defined:

10 1) Inflammatory bowel disease

11 Participants aged 4 to 17 years were extracted from an existing cohort consisting of *de novo*
12 treatment-naïve paediatric IBD patients (59 CD, 40 UC), included at the VU University
13 medical centre and the Emma Children's Hospital (AMC) between December 2013 and
14 October 2015 for a study on diagnostic biomarkers. The selection procedure is explained in
15 the Matching procedure section. All participants were instructed to collect a faecal sample
16 prior to bowel cleansing and colonoscopy. The diagnosis of IBD was made according to the
17 revised diagnostic Porto-criteria for paediatric IBD, including endoscopic, histologic and
18 radiologic findings(14). Localisation and behaviour of disease were classified according to the
19 Paris Classification(15). Clinical activity was determined at study inclusion based on the
20 Physician Global Assessment (PGA-score), levels of faecal calprotectin (FCP) and C-reactive
21 protein (CRP). Exclusion criteria were the use of anti-/probiotics or immunosuppressive
22 therapy three months prior to inclusion, immunocompromised disease (i.e. leukaemia,
23 human immunodeficiency virus), diagnosis of another gastrointestinal disease, proven
24 infectious colitis in the month before presentation (determined by positive stool culture for

1 *Salmonella spp., Shigella spp., Yersinia spp. Campylobacter spp., Clostridium spp.* toxins, or
2 parasites in stools) and a history of gastrointestinal surgery (except appendectomy).

3

4 2) IBS and FAP-NOS

5 Children aged 4 to 17 years visiting the outpatient clinic in one of the three hospitals
6 between August and December 2016, and fulfilling the ROME IV criteria for IBS or FAP-NOS
7 were eligible to participate(2). All subjects completed a questionnaire on abdominal
8 symptoms, defecation pattern based on Bristol stool chart scores, medication use and
9 medical history. Exclusion criteria were similar to the IBD subgroup.

10

11 3) Healthy controls

12 Children aged 4 to 17 years visiting elementary and high schools in the province North-
13 Holland, The Netherlands, were instructed to collect a faecal sample. Similar to the IBS/FAP-
14 NOS group, all participants completed a questionnaire containing similar items. Exclusion
15 criteria were functional gastrointestinal disorders according to the ROME IV criteria,
16 diagnosis with a gastrointestinal or immunocompromised disease, history of gastrointestinal
17 surgery (except appendectomy), or the use of pro- or antibiotics three months prior to
18 inclusion.

19

20 *Ethical considerations*

21 This study was approved by the Medical Ethical Review Committee (METc) of the VU
22 University Medical Centre under file number 2015.393, and by the local medical ethical
23 committees of other two participating centres. Written informed consent was obtained from
24 all parents, and from the child in case of age over twelve years.

1 *Matching procedure*

2 A total of 15 IBS/FAP-NOS patients (9 IBS, 6 FAP-NOS) were strictly matched to 15UC, 15CD
3 and 30HC based on age and gender. For this, the following procedure was performed. First,
4 from the 99 IBD patients (59 CD, 40 UC) of the existing cohort, all of the eligible subjects
5 were strictly matched to IBS/FAP-NOS patients. Then, IBD patients were randomly included
6 from the matched groups in a 1:1:1 ratio (IBS/FAP-NOS to UC to CD). After this, 30 HC
7 recruited for this study were matched to the IBS/FAP-NOS group in a 1:2 ratio.

8

9 *Sample collection*

10 Patients were instructed to collect a fresh faecal sample in a stool container (Stuhlgefäß
11 10ml, Frickenhausen, Germany) and instructed to store the sample in the refrigerator at
12 home directly following bowel movement. The samples were transported to the hospital by
13 one of the researchers, using cool elements and a cool bag. Here, samples were stored at -20
14 °C until further handling.

15

16 *Sample analysis*

17 Faecal volatile organic compounds analysis was performed using FAIMS (Lonestar, Owlstone
18 Ltd., UK), according to the protocol as described in an earlier study by Bomers et.al. (9). In
19 short, faecal samples were thawed to room temperature ten minutes prior to VOC analysis.
20 A mixture of 0.5g faecal sample and 3.5mL tap water was manually shaken to homogenize
21 the sample. Compressed air (0.1MPa) was used as carrier gas to transfer the sample
22 headspace (the air above the sample) into the FAIMS instrument. The Lonestar was set up in
23 a pressurised configuration with a flow rate of 2L/min. The temperatures were set at 35°C
24 for the sample holder, 70°C for the lid and 100°C for the filter region. After the procedure

1 the air in the Lonestar was refreshed by analysing the headspace of 3.5mL tap water(16).
2 The dispersion field passed through 51 equal settings between 0% and 100% (in the ratio of
3 the high electric field to low electric field). The compensation voltage was set between +6V
4 and -6V in 512 steps for each dispersion field(9). Each faecal sample was analysed three
5 times sequentially, producing three matrices in 540s. For the statistical analysis, only the
6 third matrix was used as we have previously shown that this approach gives the optimum
7 diagnostic potential(12).

8

9 *Statistical analysis*

10 The demographic data of each group (IBS/FAP-NOS, UC, CD and HC) was compared using the
11 Kruskal-Wallis-H test with the addition of the Wilcoxon-rank-sum test for continuous data.
12 The Fisher's exact tests was performed for dichotomous data using IBM SPSS version 22.
13 For FAIMS analysis, each sample consisted of 52224 data point in a 2D matrix. A pre-
14 processing method was first performed to each sample data by applying a 2D discrete
15 wavelet transform. This step aims to decompose the data and extract subtle chemical signals
16 hidden within a much larger signal. A 10 fold cross validation was then applied, where
17 feature selection and classifier training was performed to 90% of data (training set) and class
18 predictions produced from 10% of data (test set). A Wilcoxon rank sum test as feature
19 selection was used to calculate p-values in training set to identify which features are
20 optimum for disease prediction. Four classification algorithms were applied, Sparse Logistic
21 Regression, Random Forest, Gaussian Process, and Support Vector Machine. A receiver
22 operator characteristic curve was created to predict area under curve (AUC), sensitivity,
23 specificity, positive predictive value (PPV), negative predictive value (NPV), and p-values.

24

1 **Results**

2 *Baseline characteristics*

3 Baseline characteristics and disease specifics of the study subjects are displayed in Table 1.
4 There were no significant differences in age, sex and BMI between the IBS/FAP-NOS, IBD and
5 HC subgroups. In addition, no differences in faecal consistency based on the Bristol Stool
6 Chart, faecal frequency and way of delivery were found between IBS/FAP-NOS and HC.

7

8 *IBS/FAP-NOS versus IBD*

9 The results of the VOC analysis by FAIMS technique are shown in *Table 2*. For each analysis,
10 the best performing of the four different applied classification models is shown. A complete
11 overview of the data generated by the four classification models is given in supplemental
12 Table 1-4. Faecal VOCs of IBS/FAP patients differed from IBD patients (AUC \pm 95%CI,
13 sensitivity, specificity, PPV, NPV, P-values; 0.94 (0.88-1), 0.87, 0.79, 1, 0.00000002613).
14 Corresponding Receiver Operating Characteristic (ROC)-curves are visualised in *Figure 1*. An
15 overview of the complete outcome of the four performed classifiers is displayed in
16 *supplementary tables 1-2*. In addition, there were significant differences between VOC
17 profiles of IBS/FAP-NOS patients and both UC and CD subgroups (*table 2, Supp table 1-4*).

18

19 *IBS/FAP-NOS versus HC*

20 Children diagnosed with IBS/FAP could not be discriminated from HC (AUC \pm 95%CI,
21 sensitivity, specificity, PPV, NPV, P-values; (0.59 (0.41-0.77), 0.6, 0.3, 0.45, 0.76, 0.1667)
22 (*Table 2, Supp table 1-4, Figure 1*).

23

24

1 *IBD versus HC*

2 Patients with IBD could be distinguished from HC (AUC \pm 95%CI, sensitivity, specificity, PPV,
3 NPV, P-values; 0.96 (0.9-1), 0.93, 0.97, 0.97, 0.94, 0.0000000003962) (*Table 2, Supp table 1-4, Figure 1*). Both IBD subtypes UC and CD could each be differentiated from HC (*Table 2, Supp table 1-4*).

6

7 *IBS versus FAP*

8 Patients with IBS could not be discriminated from patients with FAP-NOS (AUC \pm 95%CI,
9 sensitivity, specificity, PPV, NPV, P-values; (0.76 (0.44-1), 1, 0.6, 0.83, 1, 0.9504) (*Table 2, Supp table 1-4*).

11

12 *Duration of sample storage*

13 Duration of storage of the collected faecal samples did not differ between IBS/FAP-NOS and
14 HC. IBD samples were stored for a significantly longer period compared to both other
15 subgroups (medium in months; CD 31.7; UC 45.1; IBS/FAP 0.6; HC 1.4, $P < 0.001$).

16

1 **Discussion**

2 In this multicentre case-control study, we observed that faecal VOC profiles could
3 discriminate paediatric IBS/FAP-NOS patients from children with new onset, treatment naïve
4 IBD with high accuracy, but not from HC. Furthermore, we validate earlier study results that
5 IBD and HC could be discriminated with high accuracy.

6
7 Studies on the potential of faecal VOC profiling to discriminate between paediatric IBS/FAP-
8 NOS and IBD have not yet been performed. Ahmed et. al. compared faecal VOC profiles of 30
9 adult diarrhoea-predominant IBS (IBS-D) patients, with 62 active CD, 48 active UC and 109
10 healthy subjects using gas chromatography-mass spectrometry (GC-MS)(13). In that study,
11 IBS-D could be discriminated from IBD, based on 60 statistically significant different
12 metabolites. These metabolites were used to construct a discriminatory model with high
13 diagnostic accuracy (AUC IBS-D vs CD 0.97; IBS-D vs UC 0.96; $p=0.001$). This diagnostic
14 accuracy is similar to that observed in our study. In addition, significantly increased levels of
15 28 faecal metabolites were identified in IBS-D patients compared to HC and were used for a
16 discriminatory model as well (AUC 0.92; $p<0.05$). In the present study, however, IBS/FAP-
17 NOS could not be discriminated from HC. This difference could possibly be explained by our
18 relatively small sample size. Another explanation could be our heterogeneous IBS/FAP-NOS
19 group in which subjects could experience a variety of symptoms (diarrhoea, abdominal pain,
20 bloating, constipation), whereas Ahmed. et. al. solely included patients with diarrhoea-
21 predominant IBS type. Though, we observed no significant differences in VOC profiles
22 between the two subgroups IBS and FAP-NOS. In addition, the diagnostic accuracy could
23 differ due to the fact that GC-MS is a more sensitive technique compared to FAIMS(17).
24 However, since the diagnostic accuracy to differentiate between IBD and IBS/FAP-NOS is

1 very similar between these studies, we believe this had minimal influence on our study
2 outcomes.

3 In a study performed by Walton et. al., differences in faecal VOC composition between adult
4 IBS (n=26), active CD (n=22), active UC (n=20) and HC (n=19) were assessed by means of GC-
5 MS and were found in eight metabolites, displaying gradually increased levels from HC to IBS
6 to IBD (CD>UC)(18). Unfortunately, no AUC values are given in the article, which complicates
7 comparison with our study. However, the authors did report considerable overlap of
8 compound levels between the different subgroups, and a wide dynamic range in all groups
9 including the controls.

10

11 Volatile organic compounds are considered to reflect (changes in) microbiota composition
12 and function(8). In a recent study, gut microbiota composition of patients with IBS (n=30)
13 and IBD (60 UC, 50 CD) were compared to HC (n=50) using DNA sequencing(19). Here,
14 progressive increase in abundance of species belonging to the phyla *Proteobacteria* and
15 *Firmicutes* were detected from HC to IBS to IBD, whereas *Bacteroidetes* representation was
16 gradually reduced along this spectrum. The fact that differences in the microbiota
17 composition between IBS and HC were shown in this study, whereas we did not find these
18 differences based on VOC pattern, contradicts the above mentioned hypothesis. However,
19 not all microbial changes might be reflected in corresponding alterations of VOC
20 composition. Furthermore, VOC composition is not only influenced by the gut microbiota but
21 also by systemic metabolic processes and exogenous VOCs like from diet and medication
22 (20). Despite these facts, our results are in line with the finding that microbial differences
23 between IBD and HC are larger than IBS and HC.

24

1 Until now, paediatric studies on faecal VOCs as non-invasive IBD biomarker have focussed on
2 the discrimination between IBD patients and healthy subjects, lacking a reliable exploration
3 of the specificity to discriminate IBD from IBS by VOC analysis. Main strength of this study
4 was that a paediatric IBS/FAP-NOS group was included, allowing for assessment of the
5 diagnostic accuracy in an intention-to-diagnose design. In addition, potential bias by colonic
6 lavage, colonoscopy and medication on VOC composition was circumvented in IBD patients,
7 since we only included *de novo* treatment-naïve IBD patients. Another strength is the
8 participation of three medical centres, two referral hospitals and one district hospital.
9 Furthermore, the performance characteristics of VOC analysis were assessed using
10 supervised learning models, which are suitable for high-dimensional data as they reduce
11 dimensionality. These classifiers have previously been shown effective in studies on the
12 human microbiota(21). We have decided to provide a complete overview of all learning
13 models applies in this study, as it is not known which model is most useful for VOC analysis.
14 There were also several limitations. As noted previously, the IBS/FAP-NOS group represents
15 a heterogeneous population, although no significant differences in VOC profiles were
16 observed between these two subgroups. We therefore believe that the heterogeneity of this
17 group has not significantly influenced study outcomes. Another limitation was that we have
18 not taken potential influence of medication and diet on faecal VOC outcome into account,
19 which could possibly have influenced the result(22, 23). Lastly, the potential influence of
20 sample storage time on metabolic degradation of VOCs has not yet been studied. It could be
21 hypothesized that storage duration influences VOC outcome by metabolic degradation, even
22 in frozen state. Since storage time of the IBD samples differed from that of the HC/IBS/FAP-
23 NOS samples, this may possibly have affected outcome. However, the diagnostic accuracy to
24 differentiate between IBD and HC is similar to our earlier studies, in which samples with

1 comparable storage duration were used (10). We therefore believe that metabolite
2 degradation has had no substantial influence on presented results.

3

4 Our findings implicate that faecal VOC analysis may serve as non-invasive biomarker to
5 discriminate IBS from IBD, with a higher specificity (87%) compared to the currently used
6 FCP (specificity 68%), but not IBS from healthy state. To discriminate between IBS-like
7 symptoms and active disease in the course of IBD patients with nonspecific abdominal pain
8 may be challenging in clinical practice, by limited specificity of FCP. Whether VOC analysis
9 could serve as an additional biomarker in this specific population needs to be evaluated in
10 future studies. Combination of the biomarkers FCP and faecal VOCs could possibly lower the
11 rate of unnecessary colonoscopies in the diagnostic process of IBS/FAP-NOS patients. This
12 was, however, a proof of principle study to explore the diagnostic value of faecal VOCs in
13 IBS/FAP-NOS patients. Whether this technique sufficiently contributes to this diagnostic
14 process needs to be elucidated in a larger 'intention-to-diagnose' cohort.

15

16 In conclusion, we have shown that patients with IBD could be distinguished from IBS/FAP-
17 NOS and from HC with a high diagnostic accuracy based on faecal VOC analysis using FAIMS
18 technology. This signifies its potential role as additional non-invasive biomarker in the
19 diagnostic work-up of IBD to discriminate from functional gastrointestinal disorders.

20

21

22

23

1 **References**

- 2 1 Gieteling MJ, Bierma-Zeinstra SM, Passchier J, et al. Prognosis of chronic or recurrent
3 abdominal pain in children. *J Pediatr Gastroenterol Nutr* 2008;47(3):316-26.
- 4 2 Hyams JS, Di Lorenzo C, Saps M, et al. *Functional Disorders: Children and Adolescents*.
5 Gastroenterology 2016.
- 6 3 Hoekman DR, Rutten JM, Vlieger AM, et al. Annual Costs of Care for Pediatric Irritable Bowel
7 Syndrome, Functional Abdominal Pain, and Functional Abdominal Pain Syndrome. *J Pediatr*
8 2015;167(5):1103-8 e2.
- 9 4 Levy I, Gralnek IM Complications of diagnostic colonoscopy, upper endoscopy, and
10 enteroscopy. *Best Pract Res Clin Gastroenterol* 2016;30(5):705-18.
- 11 5 van Rheenen PF, Van de Vijver E, Fidler V Faecal calprotectin for screening of patients with
12 suspected inflammatory bowel disease: diagnostic meta-analysis. *BMJ* 2010;341(c3369).
- 13 6 Zhuang X, Xiong L, Li L, et al. Alterations of gut microbiota in patients with irritable bowel
14 syndrome: A systematic review and meta-analysis. *J Gastroenterol Hepatol* 2016.
- 15 7 Weinstock GM Genomic approaches to studying the human microbiota. *Nature*
16 2012;489(7415):250-6.
- 17 8 Boots AW, Smolinska A, van Berkel JJ, et al. Identification of microorganisms based on
18 headspace analysis of volatile organic compounds by gas chromatography-mass
19 spectrometry. *J Breath Res* 2014;8(2):027106.
- 20 9 Bomers MK, Menke FP, Savage RS, et al. Rapid, accurate, and on-site detection of *C. difficile*
21 in stool samples. *Am J Gastroenterol* 2015;110(4):588-94.
- 22 10 van Gaal N, Lakenman R, Covington J, et al. Faecal volatile organic compounds analysis using
23 field asymmetric ion mobility spectrometry: non-invasive diagnostics in paediatric
24 inflammatory bowel disease. *J Breath Res* 2017.
- 25 11 de Meij TG, van der Schee MP, Berkhout DJ, et al. Early Detection of Necrotizing Enterocolitis
26 by Fecal Volatile Organic Compounds Analysis. *J Pediatr* 2015;167(3):562-7 e1.
- 27 12 Covington JA, van der Schee MP, Edge AS, et al. The application of FAIMS gas analysis in
28 medical diagnostics. *Analyst* 2015;140(20):6775-81.
- 29 13 Ahmed I, Greenwood R, Costello Bde L, et al. An investigation of fecal volatile organic
30 metabolites in irritable bowel syndrome. *PLoS One* 2013;8(3):e58204.
- 31 14 Levine A, Koletzko S, Turner D, et al. ESPGHAN revised porto criteria for the diagnosis of
32 inflammatory bowel disease in children and adolescents. *J Pediatr Gastroenterol Nutr*
33 2014;58(6):795-806.
- 34 15 Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification
35 for inflammatory bowel disease: the Paris classification. *Inflamm Bowel Dis* 2011;17(6):1314-
36 21.
- 37 16 Arasaradnam RP, Westenbrink E, McFarlane MJ, et al. Differentiating coeliac disease from
38 irritable bowel syndrome by urinary volatile organic compound analysis--a pilot study. *PLoS*
39 One 2014;9(10):e107312.
- 40 17 Arasaradnam RP, Covington JA, Harmston C, et al. Review article: next generation diagnostic
41 modalities in gastroenterology--gas phase volatile compound biomarker detection. *Aliment*
42 Pharmacol Ther 2014;39(8):780-9.
- 43 18 Walton C, Fowler DP, Turner C, et al. Analysis of volatile organic compounds of bacterial
44 origin in chronic gastrointestinal diseases. *Inflamm Bowel Dis* 2013;19(10):2069-78.
- 45 19 Lopetuso LR, Petito V, Graziani C, et al. Gut Microbiota in Health, Diverticular Disease,
46 Irritable Bowel Syndrome, and Inflammatory Bowel Diseases: Time for Microbial Marker of
47 Gastrointestinal Disorders? *Dig Dis* 2017.
- 48 20 Forbes SL, Rust L, Trebilcock K, et al. Effect of age and storage conditions on the volatile
49 organic compound profile of blood. *Forensic Sci Med Pathol* 2014;10(4):570-82.

1 21 Knights D, Costello EK, Knight R Supervised classification of human microbiota. FEMS
2 Microbiol Rev 2011;35(2):343-59.
3 22 Voreades N, Kozil A, Weir TL Diet and the development of the human intestinal microbiome.
4 Front Microbiol 2014;5(494).
5 23 Lin A, Bik EM, Costello EK, et al. Distinct distal gut microbiome diversity and composition in
6 healthy children from Bangladesh and the United States. PLoS One 2013;8(1):e53838.

7

8

1 **Table 1. Baseline characteristics**

	Crohn's disease (n=15)	Ulcerative colitis (n=15)	IBS/FAP-NOS (n=15 [9/6])	Control (n=30)
Sex, male (n [%])	9 [60]	8 [53]	8 [53]	15 [50]
Age (median [IQR]), years (minimum-maximum)	12.8 [5.0] (5.9 – 17.9)	11.8 [7.8] (3.2 – 17.8)	12.9 [8.4] (4.4 – 18.1)	12.7 [8.1] (4.1 – 17.9)
Storage time, median [IQR]), months (minimum-maximum)	31.7 [25.3]‡ (8.2 – 54.5)	45.1 [36.2]‡ (15.0 – 59.4)	0,6 [0.6]‡ (0.2 – 2.9)	1.4 [0.3]‡ (0.5 – 4.5)
BMI (median [IQR])	NA	NA	16.7 [5]	17.0 [3]
Bristol stool chart (n [%])	NA	NA		
Type 2			2 [14]*	4 [14]*
Type 3			5 [36]	19 [66]
Type 4			4 [29]	5 [17]
Type 5			3 [21]	1 [3]
Stool frequency (n [%])	NA	NA		
2 times a week or less			2 [14]*	1 [4]*
3-6 times a week			1 [7]	9 [33]
Once a day			5 [36]	14 [44]
2-3 times a day			5 [36]	4 [15]
4 times a day or more			1 [7]	1 [4]
Way of delivery	NA	NA		
Caesarean section (n [%])			3 [23]**	2 [7]*
Natural (n [%])			10 [77]	27 [93]
IBS/FAP	NA	NA	33	NA
Frequency of symptoms (IBS/FAP) (n [%])	NA	NA		NA
Once a week			4 [27]	
2 to 4 times a week			10 [66]	
Every day			1 [7]	
Duration of symptoms ((n [%])				NA
Over a year	0 [0]*	1 [7]	10 [67]	
2 to 12 months	11 [73]	7 [47]	3 [20]	
≤2 months	3 [13]	7 [47]	2 [13]	
Physician Global Assessment				
Quiescent	1	0	NA	NA
Mild	0	3	NA	NA
Moderate	5	5	NA	NA
Severe	9	7	NA	NA
Faecal calprotectin (µg/g) (median[IQR])	1214 [627-1860]	1260 [401-1950]	NA	NA
CRP (mg/l) (median[IQR])	21 [7-68]	4 [<2.5 – 7]	NA	NA
<i>Crohn's disease localisation</i> ¹				

Ileal (L1)	0	NA	NA	NA
Colonic (L2)	6	NA	NA	NA
Ileocolonic (L3)	9	NA	NA	NA
Proximal disease (L4)	5	NA	NA	NA
<i>Crohn's disease behaviour¹</i>				
B1 (NSNP)	11	NA	NA	NA
B1p (NSNP+p)	2	NA	NA	NA
B2 (S)	0	NA	NA	NA
B2p (S + p)	0	NA	NA	NA
B3 (P)	0	NA	NA	NA
B3p (P + p)	2	NA	NA	NA
<i>Ulcerative Colitis¹</i>				
Proctitis (E1)	NA	3	NA	NA
Left-sided (E2)	NA	2	NA	NA
Extensive (E3)	NA	10	NA	NA

- 1 All values were obtained at study inclusion. Localization of IBD was obtained by ileocolonoscopy and
2 esophagogastroduodenoscopy before treatment initiation, and MR enteroclysis. Abbreviations: IQR,
3 interquartile range; NA, not applicable; NSNP, non-stricturing non-penetrating; S, stricturing; P, penetrating; p,
4 peri-anal disease. ¹Based on Paris classification for inflammatory bowel disease(15).
5 * Missing data from one subject. ** Missing data from two subjects. [‡] Significant differences between all
6 subgroups p<0.001, analysed using Wilcoxon-rank-sum tests.

7

8


1 **Table 2. Performance characteristics for the discrimination of irritable bowel syndrome,**
 2 **functional abdominal pain-not otherwise specified, inflammatory bowel disease and**
 3 **healthy controls by faecal VOC analysis.**

	AUC (95% CI)	Sensitivity	Specificity	PPV	NPV	P
IBS/FAP-NOS vs IBD	0.94 (0.88 - 1)	1	0.87	0.79	1	0.0000002613
IBS/FAP-NOS vs CD	0.87 (0.73 - 1)	0.93	0.82	0.82	0.92	0.0001617
IBS/FAP-NOS vs UC	0.96 (0.91 - 1)	1	0.8	0.83	1	0.000007501
IBS/FAP-NOS vs HC	0.59 (0.41 - 0.77)	0.6	0.63	0.45	0.76	0.1667
IBS vs FAP-NOS	0.76 (0.44 - 1)	1	0.6	0.83	1	0.9504
IBD vs HC	0.96 (0.93 - 1)	0.93	0.97	0.97	0.94	0.000000003982
UC vs HC	0.98 (0.94 - 1)	0.93	0.97	0.93	0.97	0.000000005654
CD vs HC	0.95 (0.88 - 1)	0.93	0.93	0.88	0.97	0.0000001636

4 Table 2. Sensitivities, specificities, p-values and AUCs are reported for the respective optimum cut-points..
 5 Abbreviations: AUC, area under the curve; PPV: positive predictive value; NPV: negative predictive value; IBS:
 6 Irritable bowel syndrome; FAP-NOS: functional abdominal pain-not otherwise specified; IBD: Inflammatory
 7 bowel disease; UC: ulcerative colitis; CD: Crohn's disease; HC: Healthy controls.

8

1 **Figure 1. Receiver operating characteristics for irritable bowel syndrome/functional**
 2 **abdominal pain-not otherwise specified versus inflammatory bowel disease, ulcerative**
 3 **colitis and Crohn’s disease and IBD versus healthy controls.**



4
 5 Figure 1. AUCs are reported for the Sparse logistic regression analyses. Abbreviations: AUC, area under the curve;
 6 IBS: Irritable bowel syndrome; FAP-NOS: functional abdominal pain-not otherwise specified; IBD: Inflammatory
 7 bowel disease; UC: ulcerative colitis; CD: Crohn’s disease; HC: Healthy controls.